Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of emtricitabine + tenofovir alafenamide for HIV pre-exposure prophylaxis in at-risk men and transgender women
2016-001399-31Phase 3Unknown
- Sponsor
- Gilead Sciences
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Human immunodeficiency virus infection type 1 comparing Emtricitabine + tenofovir alafenamide with Emtricitabine + tenofovir disoproxil fumarate (2 arms). Primary endpoint: Incidence of HIV-1 infection per 100 person-years. Status: unknown.
02
Drugs
emtricitabinetenofovir alafenamidetenofovir disoproxil fumarate
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2016-001399-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001399-31.